(Q45778656)

16 December 2017

title

Pharmacokinetic characterization of CK2 inhibitor CX-4945. (English)

1 reference

16 December 2017

1 reference

You Hwa Son

1

1 reference

16 December 2017

Jin Sook Song

series ordinal

2

1 reference

16 December 2017

Seong Hwan Kim

series ordinal

3

1 reference

16 December 2017

Jiyeon Kim

series ordinal

4

1 reference

16 December 2017

publication date

31 March 2013

1 reference

16 December 2017

Archives of Pharmacal Research

published in

1 reference

16 December 2017

volume

36

1 reference

16 December 2017

issue

7

1 reference

16 December 2017

page(s)

840-845

1 reference

16 December 2017

https://scigraph.springernature.com/pub.10.1007/s12272-013-0103-9

exact match

0 references

cites work

Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Assessing predictors of drug-induced torsade de pointes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Protein kinase CK2 in human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Protein kinase CK2 in mammary gland tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Protein kinase CK2: structure, regulation and role in cellular decisions of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Role for casein kinase 2 in the regulation of HIF-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

The selectivity of inhibitors of protein kinase CK2: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Dose-independent pharmacokinetics of a new peroxisome proliferator-activated receptor-γ agonist, KR-62980, in Sprague-Dawley rats and ICR mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Pharmacokinetics in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Resorufin: a lead for a new protein kinase CK2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Protein kinase CK2 as a druggable target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-013-0103-9

Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.3109/00498254.2011.587551

Identifiers

DOI

10.1007/S12272-013-0103-9

1 reference

16 December 2017

Dimensions Publication ID

1029763535

0 references

1 reference

16 December 2017